New drug combo strategy aims to outsmart advanced breast cancer
NCT ID NCT07151586
Summary
This study is testing if alternating between two newer, targeted cancer drugs can help patients with advanced triple-negative breast cancer live longer than using just one of the drugs. It will involve about 260 adults whose cancer has spread or cannot be removed by surgery. The main goal is to see if this alternating approach can better control the cancer and delay its progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER 2 LOW-EXPRESSING BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Gustave Roussy
Villejuif, 94800, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
institut Paoli calmette
Marseille, 13009, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.